Clinical Context
A typical patient is an adolescent or adult with Duchenne muscular dystrophy (DMD) who is eligible for targeted exon-skipping therapy with casimersen. The patient presents to an outpatient infusion or specialty injection clinic for administration of J1426 (injection, casimersen, 10 mg). Prior to the visit, the patient’s prescription is verified against the medical record confirming the dystrophin gene mutation amenable to exon 45 skipping. Baseline vitals, height/weight for dose calculation, and recent laboratory tests (liver function tests, renal panel) are reviewed. The medication is prepared by pharmacy and delivered to the clinic in a nursing area certified for specialty biologic handling. A registered nurse performs pre-injection assessment, verifies site of service, confirms informed consent and allergies, and documents any prior adverse reactions to antisense oligonucleotide therapies. The nurse administers the intravenous or subcutaneous injection per manufacturer guidance (site, rate), observes the patient for acute infusion-related or hypersensitivity reactions for a monitored recovery period, and documents lot number, dose, and administration route in the medical record. If an adverse event occurs, the clinic applies appropriate emergency measures and documents the event. Follow-up scheduling is arranged for ongoing regular dosing and laboratory monitoring as specified in the prescribing information.
Coding Specifications
| Modifier | Description | When to Use |
|---|
00 | No modifier | Use when no modifier applies to the service. |
| 22 | Increased procedural services | Use when additional work or complexity beyond typical administration occurs (documented and justified).
| 23 | Unusual anesthesia | Use if unusual anesthesia is required for injection administration (rare for this drug).
| 52 | Reduced services | Use when the full dose or complete service was not rendered and is documented.
| 53 | Discontinued procedure | Use when administration is started but discontinued due to patient condition or reaction.
| 62 | Two surgeons | Use when two qualified providers are involved in the procedure (rare for medication administration).
| 78 | Return to OR following initial procedure | Not typically applicable; use only if post-procedural return occurs related to administration complications.
| AS | Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant at surgery | Use when an advanced practice clinician assists in the procedure per payer rules.
| QX | CRNA service: furnished with qualified anesthesia personnel | Use when a certified registered nurse anesthetist provides anesthesia services during administration.
| QY | CRNA service: medically directed by anesthesiologist | Use when CRNA services are medically directed per payer policy.
| SH | Speech-language pathology services — assistant | Use only if a related multidisciplinary service is billed in the same encounter.
| SJ | Supplemental payment for certain services | Use only when applicable per payer policies that recognize SJ for specific supplemental payments.
| Taxonomy Code | Specialty | Notes |
|---|
208000000X | Neurology | Neurologists manage Duchenne muscular dystrophy and prescribe exon-skipping therapies. |
| 207RC0000X | Pediatric Neurology | Pediatric neurologists evaluate and initiate therapy in children and adolescents with DMD.
| 363L00000X | Hematology & Oncology (Infusion Specialist) | Infusion clinic physicians or specialists oversee complex biologic administration workflows.
| 286100000X | Nurse Practitioner | NPs frequently perform medication assessment and administer or supervise injections in specialty clinics.
| 164W00000X | Emergency Medicine | EM physicians may be involved for management of acute hypersensitivity or infusion reactions.
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|
G71.01 | Duchenne muscular dystrophy | Primary indication for casimersen in patients with DMD amenable to exon 45 skipping. |
| R53.1 | Weakness | Common clinical symptom in DMD patients receiving supportive exon-skipping therapy.
| Z79.899 | Other long term (current) drug therapy | Used to indicate ongoing long-term medication therapy such as chronic casimersen administration.
| Z51.89 | Encounter for other specified aftercare | Used for routine follow-up visits related to ongoing treatment and monitoring after initiation of therapy.
| T78.4XXA | Allergy, unspecified, initial encounter | Relevant for documenting hypersensitivity or allergic reactions to medications during or after administration.
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|
96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | Used when casimersen is administered as an IV infusion requiring timed infusion monitoring for the first hour. |
| 96366 | Intravenous infusion, each additional hour (List separately in addition to code for primary IV infusion) | Used if infusion of casimersen requires additional time beyond the initial hour.
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | Used when casimersen is administered as a single subcutaneous or intramuscular injection per route allowed.
| 96413 | Chemotherapy administration, IV infusion technique; up to 1 hour, single or initial substance/drug | Used in some payor policies for biologic or complex IV drug administration when billed under chemotherapy-style infusion codes.
| 99070 | Supplies and materials (except spectacles), noncovered items billed separately by physician | Used to report expendable supplies associated with administration (e.g., IV tubing, syringes) when payor allows separate billing.